Search
Fidaxomicin
go.drugbank.com/drugs/DB08874ApprovedInvestigational[A190501] Because fidaxomicin contains an 18-membered lactone ring in its structure, it is referred to as a macrocyclic lactone antibiotic drug.
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP3A InhibitorsParicalcitol
go.drugbank.com/drugs/DB00910ApprovedInvestigationalParicalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels.
Categories: Vitamin D and Analogues, Cytochrome P-450 SubstratesSynonyms: 19-Nor-1alpha,25-dihydroxyvitamin D2Entrectinib
go.drugbank.com/drugs/DB11986ApprovedInvestigational[L8207] Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. … This therapy offers benefit over similar ALK inhibitors such as [alectinib], [ceritinib], and [lorlatinib] due to a wider range of targets.[A183929]
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesPimivalimab
go.drugbank.com/drugs/DB16667InvestigationalPimivalimab is under investigation in clinical trial NCT04549025 (Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After
Pixatimod
go.drugbank.com/drugs/DB19166InvestigationalPixatimod is under investigation in clinical trial NCT05061017 (Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide
Synonyms: Pg-545 free acidCabotegravir
go.drugbank.com/drugs/DB11751ApprovedInvestigationalCabotegravir, or GSK1265744, is an HIV-1 integrase inhibitor that is prescribed with the non-nucleoside reverse transcriptase inhibitor, [rilpivirine]. … [L31198] While previously administered once monthly only, this combination product was granted FDA approval for dosing every two months on February 01, 2022 [L40084] and without the need for an oral lead-in
Categories: P-glycoprotein substratesRemifentanil
go.drugbank.com/drugs/DB00899ApprovedInvestigationalRemifentanil is a specific mu-type-opioid receptor agonist which means it reduces sympathetic nervous system tone, and causes respiratory depression and analgesia. … Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid given to patients during surgery for pain relief and adjunctive to an anaesthetic.
Enzalutamide
go.drugbank.com/drugs/DB08899ApprovedInvestigational[A252667,A252642] Due to a favorable pharmacological profile, a phase 1 study of enzalutamide was initiated in July 2007. … [A252667] Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesNirogacestat
go.drugbank.com/drugs/DB12005ApprovedInvestigational[A262556] Interaction between the notch receptors and their ligands activates proteolytic cleavage by gamma-secretase; therefore, the inhibition of gamma-secretase can potentially inhibit Notch signaling
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesEquine Botulinum Neurotoxin B Immune FAB2
go.drugbank.com/drugs/DB13903ApprovedEquine Botulinum Neurotoxin B Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype B. It is intravenously administered for the treat...